Histone

Global Epigenetics Market Analysis and Forecast 2021-2031: Focus on Product, Mechanism, Technology, Application, End User and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, February 11, 2022
Health, Genetics, Health, Whole genome sequencing, Adoption, Prognosis, Lists of diseases, DNA methylation, Biomarker, Region, RNA, Degenerative disease, Cros, PCR, Neurodegeneration, Biotechnology, Medication, Health care, Cell, Polymerase, Histone, Growth, Research, Diagnosis, DNA, COVID-19, Polymerase chain reaction, Contract, Flow cytometry, CAGR, Gene, Medical device, Uranium, Fine chemical, Technology

The "Epigenetics Market - A Global and Regional Analysis: Focus on Product, Mechanism, Technology, Application, End User, and Region - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epigenetics Market - A Global and Regional Analysis: Focus on Product, Mechanism, Technology, Application, End User, and Region - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • Healthcare experts have found the epigenetics market to be one of the highest booming markets, and the global market is predicted to grow at a CAGR of 17.11% during the forecast period 2021-2031.
  • What are the major market drivers, challenges, and opportunities in the global epigenetics market?
  • Who are the leading players with significant offerings in the global epigenetics market?

Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production

Retrieved on: 
Monday, October 4, 2021
Patent, Partnership, Degenerative disease, Inflammation, Sale, KUBE (FM), Atherosclerosis, Neutrophil extracellular traps, DNA, FDA, Cancer, Infection, Stem cell, Big Pharma, Histone, CEO, Company, Germination, ELK, OTC Markets Group, COVID-19, Cell, Neutrophil, Exosome, B cell, Enzyme, Transfusion-related acute lung injury, Pharmaceutical industry

ELK CITY, Idaho, Oct. 4, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today laboratory data demonstrating that exosomes produced by JadiCells, the Company's Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps.

Key Points: 
  • ELK CITY, Idaho, Oct. 4, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today laboratory data demonstrating that exosomes produced by JadiCells, the Company's Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps.
  • Neutrophil extracellular traps are a network of extracellular DNA, histones, and enzymes that cause inflammation.In healthy individuals, neutrophil extracellular traps are very useful in fighting bacterial infections.
  • Unfortunately, in conditions such as COVID-19, atherosclerosis, cancer, and various autoimmune diseases, neutrophil extracellular traps are considered to play a major role in disease initiation and progression1.
  • In a series of experiments JadiCells and other mesenchymal stem cells were stimulated using agents that replicate biological "danger signals".

Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma

Retrieved on: 
Monday, August 16, 2021
Dysgeusia, Common, Phosphorylation, S-Adenosyl methionine, Cell division, Refractory, Lymphoma, Gene, Incidence, Eisai, Continuity, Science, Efficiency, Molecular Cancer Research, Research, DNA, Methylation, Nature Genetics, Genetics, Ageing, American Association for Cancer Research, Therapy, Diffuse large B-cell lymphoma, ORR, Automation, Carcinogenesis, Acetylation, Mutation, Review, Follicular lymphoma, EZH2, Advanced manufacturing, Safety, Adult, Blood, Patient, Lymphocytopenia, Relapse, Neoplasm, FDA, Veni, vidi, vici, Histone, Technology, Gene expression, Vaccine, Fine chemical, Pharmaceutical industry, Wood drying

This agent selectively inhibits EZH2 in a competitive matter with S-adenosylmethionine (a methyl group donor) to suppress methylation of H3K27.

Key Points: 
  • This agent selectively inhibits EZH2 in a competitive matter with S-adenosylmethionine (a methyl group donor) to suppress methylation of H3K27.
  • Eisai was one of the first to adopt Continuous Manufacturing system (CTS-MiGRA) and applied this technology to the production of this agent.
  • Study 206 enrolled patients with EZH2 gene mutation-positive, primarily follicular lymphoma, who had relapsed or were refractory.
  • Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin.

Kanazawa University research: Unraveling DNA packaging

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Nucleic acids, Molecular genetics, DNA-binding proteins, DNA, Histone, RNA, Molecular models of DNA

b'KANAZAWA, Japan, April 28, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Physical Chemistry Letters how high-speed atomic force microscopy can be used for studying DNA wrapping processes.

Key Points: 
  • b'KANAZAWA, Japan, April 28, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Physical Chemistry Letters how high-speed atomic force microscopy can be used for studying DNA wrapping processes.
  • DNA is very long for humans, the molecule is estimated to be about 2 m in length.
  • In cells, DNA occurs in a densely packed form, with strands of the molecule coiled up in a complicated but efficient space-filling way.
  • A key role in DNA\'s compactification is played by histones, structural-support proteins around which a part of a DNA molecule can wrap.

Kanazawa University research: Unraveling DNA packaging

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Nucleic acids, Molecular genetics, DNA-binding proteins, DNA, Histone, RNA, Molecular models of DNA

b'KANAZAWA, Japan, April 28, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Physical Chemistry Letters how high-speed atomic force microscopy can be used for studying DNA wrapping processes.

Key Points: 
  • b'KANAZAWA, Japan, April 28, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Physical Chemistry Letters how high-speed atomic force microscopy can be used for studying DNA wrapping processes.
  • DNA is very long for humans, the molecule is estimated to be about 2 m in length.
  • In cells, DNA occurs in a densely packed form, with strands of the molecule coiled up in a complicated but efficient space-filling way.
  • A key role in DNA\'s compactification is played by histones, structural-support proteins around which a part of a DNA molecule can wrap.

ORYZON Starts Preclinical Collaboration on Autism with the Seaver Autism Center at Mount Sinai

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Epigenetics, Biology, Proteins, Seaver Autism Center, H3K4, Histone

This collaboration will explore the effects of vafidemstat in animal models developed and characterized at the Seaver Autism Center by the team of Dr. Buxbaum.

Key Points: 
  • This collaboration will explore the effects of vafidemstat in animal models developed and characterized at the Seaver Autism Center by the team of Dr. Buxbaum.
  • Dr. Carlos Buesa, Oryzons CEO, said: "We are excited to initiate this collaboration with researchers at the internationally renowned Seaver Autism Center at Mount Sinai.
  • Epigenetic dysregulation in the histone H3K4 methylation pathway has been proposed to be an important mechanism in the pathogenesis of autism.
  • Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon.

Pipeline Review for Histone Deacetylase 3, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 19, 2020
Health, Pharmaceutical, Branches of biology, Proteins, Genetics, Histone deacetylase, HDAC3, Histone, Histone deacetylase 5, HDAC9

The "Histone Deacetylase 3 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Histone Deacetylase 3 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene.
  • Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events.
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 16 molecules.

Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

Retrieved on: 
Tuesday, March 24, 2020
Branches of biology, BET inhibitor, Proteins, Chemistry, Bromodomain, Apabetalone, Epigenetics, BRD2, BET, Acetylation, BRD, Histone

BRD2 is a member of the bromodomain and extra-terminal (BET) domain family whose members bind acetylated histones to regulate gene transcription.

Key Points: 
  • BRD2 is a member of the bromodomain and extra-terminal (BET) domain family whose members bind acetylated histones to regulate gene transcription.
  • This novel research is certainly very encouraging and warrants additional testing of apabetalone, our investigational phase 3 clinical candidate with safety data in more than 4,000 subjects, said Donald McCaffrey, President and CEO of Resverlogix.
  • Interested COVID-19 collaborators can contact:
    Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.
  • Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.

Histone Deacetylase 8, Pipeline Review, H1 2020: Analysis by Indications, Stage of Development, Mechanism of Action & Route of Administration - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 29, 2020
Biotechnology, Pharmaceutical, Health, Branches of biology, HDAC8, Proteins, Histone deacetylase, Histone, Protein deacetylase, Histone deacetylase inhibitor

The "Histone Deacetylase 8 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Histone Deacetylase 8 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene.
  • Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules.
  • The latest report Histone Deacetylase 8 - Pipeline Review, H1 2020, outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Lysine N Methyltransferase EZH2, Pipeline Review, H2 2019 - Domainex Ltd, Kainos Medicine Inc, Epizyme Inc & Pfizer Inc - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 16, 2020
Biotechnology, Pharmaceutical, Genetics, Health, Branches of biology, Epigenetics, EZH2, Ezh2 gene, Proteins, Protein families, N-methyltransferase, Histone methyltransferase, Histone, EZH1, Polycomb Group Proteins and Cancer

The "Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019'; Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 19 molecules.
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene.
  • The report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019' outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.